Daily Ards Research Analysis
Three ARDS-focused studies advance therapeutic and diagnostic avenues: primed MSC-derived extracellular vesicles enhanced anti-inflammatory and reparative effects in ALI models, leukotriene pathway inhibitors curtailed neutrophil-driven inflammation in a murine ARDS model, and bioinformatic analyses identified ER-stress hub genes (STAT3 up, YWHAQ down) validated in clinical samples. Together, they propose cell-free regenerative therapy, drug repurposing targets, and diagnostic biomarkers for sep
Summary
Three ARDS-focused studies advance therapeutic and diagnostic avenues: primed MSC-derived extracellular vesicles enhanced anti-inflammatory and reparative effects in ALI models, leukotriene pathway inhibitors curtailed neutrophil-driven inflammation in a murine ARDS model, and bioinformatic analyses identified ER-stress hub genes (STAT3 up, YWHAQ down) validated in clinical samples. Together, they propose cell-free regenerative therapy, drug repurposing targets, and diagnostic biomarkers for sepsis-associated ARDS.
Research Themes
- Cell-free regenerative therapy using primed MSC-derived extracellular vesicles
- Leukotriene pathway inhibition to modulate neutrophil-driven ARDS inflammation
- Endoplasmic reticulum stress biomarkers for sepsis-associated ARDS
Selected Articles
1. Inflammatory cytokine-primed MSC-derived extracellular vesicles ameliorate acute lung injury via enhanced immunomodulation and alveolar repair.
Cytokine priming of hADMSC-derived EVs enhanced their anti-inflammatory and barrier-repair functions compared with unprimed EVs across cell assays, an LPS-induced ALI mouse model, and a SARS-CoV-2 infection model. Mechanistic data linked efficacy to increased immunosuppressive molecules in parent cells and elevated EV miRNAs (e.g., miR-221-3p).
Impact: Introduces a scalable, cell-free therapeutic strategy with enhanced potency for ALI/ARDS and viral lung injury, addressing a major treatment gap. Mechanistic insights into EV cargo strengthen translatability.
Clinical Implications: Supports development of primed MSC-EVs as an adjunctive ARDS therapy. Next steps include dose-finding, safety, and biodistribution studies, with attention to manufacturing standardization and potency assays.
Key Findings
- Primed hADMSCs upregulated COX-2, IDO, and TSG-6 without altering EV morphology or yield.
- P-MEVs outperformed control EVs in suppressing cytokines and immune cell infiltration and in reducing lung injury markers in LPS-induced ALI mice.
- P-MEVs mitigated cytopathic effects and inflammatory responses in SARS-CoV-2–infected cells, associated with elevated EV miRNAs including miR-221-3p.
Methodological Strengths
- Multi-system validation (human cell lines, murine ALI model, viral infection model)
- Comprehensive EV characterization and mechanistic linkage to miRNA cargo
Limitations
- LPS-induced ALI may not fully recapitulate heterogeneous human ARDS pathophysiology.
- Lack of pharmacokinetics, dosing optimization, and in vivo safety/toxicology data.
Future Directions: Validate in additional ARDS models and large animals, define dose and route, establish GMP-grade manufacturing and potency assays, and initiate early-phase clinical trials.
BACKGROUND: Acute lung injury (ALI) is characterized by excessive inflammation and alveolar damage, arising from pathogens or systemic insults such as sepsis, and can progress to severe acute respiratory distress syndrome (ARDS). Despite its severity, effective pharmacological treatments remain unavailable, and current clinical interventions are limited to supportive care such as mechanical ventilation. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising candidates for lung repair, but insufficient immunosuppressive capacity often limits their efficacy. METHODS: Human adipose-derived mesenchymal stem cells (hADMSCs) were primed with IFN-γ and TNF-α to enhance the immunomodulatory properties of their secreted EVs. We characterized unprimed control MSC-EVs (C-MEVs) and primed MSC-EVs (P-MEVs) by transmission electron microscopy, nanoparticle tracking analysis, and western blotting for EV markers. Functional assays in THP-1 and A549 cells examined anti-inflammatory potency and barrier regeneration against lipopolysaccharide (LPS)-induced damage. A preclinical mouse model of LPS-induced ALI was used to evaluate inflammatory cytokine expression, immune cell infiltration, pulmonary edema, and vascular leakage. Finally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected Vero E6 cells were tested whether P-MEVs could mitigate the inflammatory damage characteristic of virus-triggered acute lung injury. RESULTS: Primed hADMSCs exhibited elevated expression of immunosuppressive molecules (e.g., COX-2, IDO, TSG-6), without changing EV morphology or yield. P-MEVs mitigated LPS-induced inflammation more effectively than C-MEVs in THP-1 and A549 cells. In vivo, P-MEVs more robustly attenuated inflammatory cytokines, immune cell recruitment, and lung injury markers in mice challenged with LPS. In SARS-CoV-2-infected Vero E6 cells, P-MEVs suppressed cytopathic effects and inflammatory responses more potently than C-MEVs. Mechanistic analyses revealed that these enhancements were associated with elevated miRNA levels, including miR-221-3p, involved in inhibiting inflammatory pathways. CONCLUSION: Inflammatory cytokine priming substantially augments the immunomodulatory and tissue-regenerative efficacy of hADMSC-derived EVs, offering superior therapeutic effects in ALI models and promising activity against SARS-CoV-2-induced lung damage. These findings underscore the therapeutic potential of P-MEVs as an innovative, cell-free platform for treating severe pulmonary disorders, including ARDS.
2. Modulation of Neutrophil Recruitment and Inflammatory Signaling in Acute Respiratory Distress Syndrome by Leukotriene Inhibitors Montelukast and Zileuton.
In an LPS-induced murine ARDS model, montelukast and zileuton reduced neutrophil infiltration, adhesion molecule expression, and BAL cytokines, and impaired human neutrophil chemotaxis in vitro. Mechanistically, leukotriene pathway blockade downregulated CysLTR1 and ERK1/2 responses after inflammatory stimulation.
Impact: Provides mechanistic and translational evidence supporting repurposing of approved leukotriene modifiers to dampen neutrophil-driven inflammation in ARDS.
Clinical Implications: Supports feasibility of rapid clinical translation to test leukotriene inhibitors as adjuncts in ARDS. Trial design should consider timing (early post-injury), dosing, and safety monitoring.
Key Findings
- Both montelukast and zileuton significantly reduced lung and BAL neutrophil infiltration (p < 0.01).
- Adhesion molecules (PSGL-1, L-selectin, LFA-1) and BAL cytokines (TNF-α, CXCL2, IL-1β, IL-6) were decreased after treatment (p < 0.05).
- In vitro, neutrophil chemotaxis and expression of CysLTR1 and ERK1/2 were reduced following inflammatory stimulation.
Methodological Strengths
- Combined in vivo ARDS model with human neutrophil in vitro assays
- Multiple complementary readouts (histology, flow cytometry, ELISA, qPCR) with timed post-injury intervention
Limitations
- Single LPS-induced injury model without survival outcomes or multi-hit validation.
- No pharmacokinetic/safety data or comparison with standard-of-care therapies.
Future Directions: Evaluate in diverse ARDS models (bacterial, viral, sterile), define optimal dosing and timing, assess safety, and proceed to early-phase clinical trials, potentially with biomarker-guided enrichment.
Acute respiratory distress syndrome (ARDS) is characterized by excessive neutrophil-driven inflammation and remains a leading cause of mortality in critical care. Leukotriene-modifying agents, such as montelukast (a CysLTR1 antagonist) and zileuton (a 5-lipoxygenase inhibitor), are approved for chronic inflammatory lung diseases, but their role in ARDS is unclear. We investigated the effects of montelukast and zileuton in a murine model of lipopolysaccharide (LPS)-induced ARDS, supported by in vitro assays using human neutrophils. Mice were treated with either drug 1 h post-injury. Neutrophil recruitment, cytokine release, and inflammatory signaling were assessed by immunohistochemistry, flow cytometry, ELISA, and qPCR. Neutrophil chemotaxis and signaling responses were evaluated in vitro. Both montelukast and zileuton significantly reduced neutrophil infiltration into lung tissue and bronchoalveolar lavage fluid (p < 0.01), suppressed expression of adhesion molecules (PSGL-1, L-selectin, LFA-1), and decreased levels of TNF-α, CXCL2, IL-1β, and IL-6 in BAL fluid (p < 0.05). In vitro, both drugs impaired neutrophil chemotaxis and reduced CysLTR1 and ERK1/2 expression following inflammatory stimulation. These findings indicate that leukotriene pathway inhibition limits neutrophil recruitment and activation in ARDS by modulating receptor expression and ERK1/2 signaling. Montelukast and zileuton may offer a targeted strategy to attenuate hyperinflammation in ARDS.
3. Identification and analysis of the endoplasmic reticulum stress hub genes in sepsis-associated ARDS.
Integrative bioinformatics and machine learning identified five ER-stress-related hub genes in sepsis-associated ARDS, with STAT3 upregulation and YWHAQ downregulation validated by RT-qPCR in clinical samples. ROC analyses suggested diagnostic discrimination for all five candidates.
Impact: Provides prioritized ER-stress biomarkers with initial clinical validation, linking pathophysiology to potential diagnostics and therapeutic targets in sepsis-associated ARDS.
Clinical Implications: Suggests STAT3 and YWHAQ as candidate biomarkers for diagnosing or stratifying sepsis-associated ARDS and as potential targets for ER-stress–modulating therapies, pending validation in independent cohorts.
Key Findings
- Identified 438 DEGs and five ER-stress hub genes (STAT3, HSPB1, YWHAQ, LCN2, SGK1) in sepsis-associated ARDS versus healthy controls.
- All five genes showed favorable ROC-based discriminatory performance for diagnostic utility.
- RT-qPCR validation in clinical samples confirmed significant upregulation of STAT3 and downregulation of YWHAQ.
Methodological Strengths
- Integrated WGCNA, immune infiltration analysis, and three machine learning methods (LASSO, RF, SVM)
- Experimental validation via RT-qPCR in clinical samples
Limitations
- Reliance on a single public dataset with potential batch effects and limited clinical covariates.
- Sample size and external validation cohort details are not provided; functional mechanistic validation is limited.
Future Directions: Validate biomarkers in independent, multicenter cohorts (including sepsis without ARDS), develop multi-gene panels, and perform functional studies to link ER-stress signaling to ARDS phenotypes.
Acute respiratory distress syndrome (ARDS) is one of the most common and serious complications in the development of sepsis. Endoplasmic reticulum stress (ERS) plays an important role in the pathophysiologic process of sepsis-associated ARDS. The aim of this study was to identify and analyze hub genes related to ERS in sepsis-associated ARDS using bioinformatics and machine learning algorithms, which may serve as diagnostic markers and therapeutic targets. Based on the GSE32707 dataset from the GEO database, differentially expressed genes (DEGs) between patients with sepsis-associated acute respiratory distress syndrome (ARDS) and healthy controls were identified. A comprehensive evaluation was performed by integrating functional enrichment analysis, immune cell infiltration analysis, and weighted gene co-expression network analysis (WGCNA). By intersecting DEGs, key WGCNA module genes, and ERS-related genes(ERGs), ERS-associated differential genes in sepsis-related ARDS were obtained. Subsequently, three machine learning algorithms-least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM)-were used to further screen for hub ERS hub genes. The diagnostic value of these hub genes was assessed using receiver operating characteristic (ROC) curve analysis. Finally, their expression levels were validated in clinical samples using RT-qPCR. A total of 438 DEGs and five hub genes-STAT3, HSPB1, YWHAQ, LCN2, and SGK1-were identified.Diagnostic performance analysis demonstrated that all five genes had favorable discriminatory power, indicating their potential clinical utility.Further validation in clinical samples confirmed the reliability of the bioinformatics analysis. RT-qPCR results showed that STAT3 was significantly upregulated, while YWHAQ was significantly downregulated in sepsis-associated ARDS samples compared to healthy controls, with both differences reaching statistical significance. In conclusion, STAT3 and YWHAQ, as ERS-related key genes, not only play pivotal roles in sepsis-associated ARDS but also hold promise as diagnostic biomarkers and potential therapeutic targets.